Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLQ | O75417 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4278709 | 0.78 | RECQL (0.50) | CYP1A2CYP2C19ALDH1A1RECQLPOLB | |
| SCHEMBL24226816 | 0.78 | ALDH1A1 (0.39) | CYP1A2CYP2C19ALDH1A1TSHRMAPT | |
| SCHEMBL29770615 | 0.76 | ALDH1A1 (0.38) | CYP1A2CYP2C19ALDH1A1RECQLPOLB | |
| SCHEMBL16466177 | 0.76 | RECQL (0.40) | CYP1A2CYP2C19ALDH1A1RECQLPOLB | |
| SCHEMBL16387120 | 0.76 | ALDH1A1 (0.38) | CYP1A2CYP2C19ALDH1A1RECQLPOLB | |
| SCHEMBL13351317 | 0.76 | MAPT (0.39) | CYP1A2CYP2C19ALDH1A1POLBTSHR | |
| SCHEMBL19789223 | 0.76 | ALDH1A1 (0.38) | CYP1A2CYP2C19ALDH1A1POLQ | |
| SCHEMBL25477654 | 0.73 | ALDH1A1 (0.35) | CYP1A2CYP2C19ALDH1A1POLQ | |
| SCHEMBL17813862 | 0.73 | CA2 (0.36) | CYP1A2CYP2C19ALDH1A1POLBTSHR | |
| SCHEMBL17813866 | 0.73 | ALDH1A1 (0.35) | CYP1A2CYP2C19ALDH1A1POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022109001-A1 | GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2022-05-27 | — | — | WO | disclosed |
| US-20140343084-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8883790-B2 | Pharmaceutical combinations | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-11 | — | — | US | disclosed |
| US-8815926-B2 | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases | NOVARTIS AG (CH) | 2014-08-26 | — | — | US | disclosed |
| US-8629137-B2 | CGRP antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-14 | — | — | US | disclosed |
| US-20140011798-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| US-20130029975-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| EP-2386558-A1 | CGRP antagonists | Boehringer Ingelheim International GmbH (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-05-05 | — | — | US | disclosed |
| US-20110059954-A1 | CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059954-A1 | CGRP ANTAGONISTS | CALCRL, CALCR, CALCA | CYP1A2 1748/4885CYP2C19 1336/4885ALDH1A1 1292/4885 |
| US-20140011798-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | MDM4, MDM2, TP53 | CYP1A2 2781/4885CYP2C19 2949/4885ALDH1A1 2047/4885 |
| US-20130029975-A1 | CGRP ANTAGONISTS | CALCRL, CALCR, CALCA | CYP1A2 1748/4885CYP2C19 1336/4885ALDH1A1 1292/4885 |
| US-20140343084-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | MDM4, MDM2, TP53 | CYP1A2 2781/4885CYP2C19 2949/4885ALDH1A1 2047/4885 |
| US-20110105501-A1 | PHARMACEUTICAL COMBINATIONS | GSK3B, CDK1, GSK3A | CYP1A2 995/4885CYP2C19 900/4885ALDH1A1 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.